Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices 84609 

reasonably close geographic proximity 

to the delineated borders of one of 

ITCN’s member tribes, as required in 45 

CFR 98.61(c) and 98.83(b), and as 

described in the Program Instruction 

CCDF–ACF–PI–2022–03. As a result, 

OCC adjusted ITCN’s child count 

downward. 

CCDF regulations prescribe that 

reconsideration shall be conducted by 

hearing governed by 45 CFR part 99. 

The ACF Director of Office of Grants 

Policy, Latasha Abney, is the designated 

presiding officer. The presiding officer 

has authority to ‘‘modify or waive any 

rule in [Part 99] upon determination 

that no party will be unduly prejudiced 

and the ends of justice will thereby be 

served.’’ 45 CFR 99.4. 

45 CFR 99.15 allows recognition of 

other individuals or groups as parties ‘‘if 

the issues to be considered at the 

hearing have directly caused them 

injury and their interests to be protected 

by the governing Federal statute and 

regulations.’’ This Federal Register 

notice serves as notification to other 

parties who may have interest in this 

hearing. Individuals or groups desiring 

to participate as parties should submit 

a petition in writing to presiding officer, 

Latasha Abney, at the address above 

within 15 days of publication of this 

notice. Such petition shall concisely 

state (i) Petitioner’s interest in the 

proceeding; (ii) Who will appear for 

petitioner; (iii) The issues on which 

petitioner wishes to participate; and (iv) 

Whether petitioner intends to present 

witnesses. A copy of the petition must 

also be served on ITCN Executive 

Director, Deserea Quintana at 

dquintana@itcn.org. The presiding 

officer will promptly determine whether 

each petitioner has the requisite interest 

and shall permit or deny participation 

accordingly. 

45 CFR 99.22 allows parties to (a) 

Appear by counsel or other authorized 

representative, in all hearing 

proceedings; (b) Participate in any 

prehearing conference held by the 

presiding officer; (c) Agree to 

stipulations as to facts which will be 

made a part of the record; (d) Make 

opening statements at the hearing; (e) 

Present relevant evidence on the issues 

at the hearing; (f) Present witnesses who 

then must be available for crossexamination by all other parties; (g) 

Present oral arguments at the hearing; 

and (h) Submit written briefs, proposed 

findings of fact, and proposed 

conclusions of law, after the hearing. 45 

CFR 99.23 allows that ‘‘The Department, 

the Lead Agency, and any individuals or 

groups recognized as parties shall have 

the right to conduct discovery 

(including depositions) against 

opposing parties,’’ and that Rules 26–37 

of the Federal Rules of Civil Procedure 

shall apply to discovery proceedings. 

Pursuant to 45 CFR 99.32, at the 

conclusion of the hearing and 

completion of post-hearing briefs, if any, 

the presiding officer shall certify the 

record and provide recommended 

finding and a proposed decision to the 

Assistant Secretary. Any party will then 

have 20 days to file exceptions and a 

supporting brief or statement with the 

Assistant Secretary. The decision of the 

Assistant Secretary shall be the final 

agency action on the matter. 

All written material provided by ACF, 

ITCN, and any other recognized party 

will be included in the administrative 

record. 

Megan E. Steel, 

ACF Certifying Officer. Administration for 

Children and Families. 

[FR Doc. 2024–23441 Filed 10–22–24; 8:45 am] 

BILLING CODE 4184–87–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Notice of Interest Rate on Overdue 

Debts 

Section 30.18 of the Department of 

Health and Human Services’ claims 

collection regulations (45 CFR part 30) 

provides that the Secretary shall charge 

an annual rate of interest, which is 

determined and fixed by the Secretary 

of the Treasury after considering private 

consumer rates of interest on the date 

that the Department of Health and 

Human Services becomes entitled to 

recovery. The rate cannot be lower than 

the Department of Treasury’s current 

value of funds rate or the applicable rate 

determined from the ‘‘Schedule of 

Certified Interest Rates with Range of 

Maturities’’ unless the Secretary waives 

interest in whole or part, or a different 

rate is prescribed by statute, contract, or 

repayment agreement. The Secretary of 

the Treasury may revise this rate 

quarterly. The Department of Health and 

Human Services publishes this rate in 

the Federal Register. 

The current rate of 123⁄8%, as fixed by 

the Secretary of the Treasury, is certified 

for the quarter ended September 30, 

2024. This rate is based on the Interest 

Rates for Specific Legislation, ‘‘National 

Health Services Corps Scholarship 

Program (42 U.S.C. 254o(b)(1)(A))’’ and 

‘‘National Research Service Award 

Program (42 U.S.C. 288(c)(4)(B)).’’ This 

interest rate will be applied to overdue 

debt until the Department of Health and 

Human Services publishes a revision. 

David C. Horn, 

Director, Office of Financial Policy and 

Reporting. 

[FR Doc. 2024–24510 Filed 10–22–24; 8:45 am] 

BILLING CODE 4150–04–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Feasibility of Novel 

Diagnostics for TB in Endemic Countries 

(FEND for TB) (R01—Clinical Trial Not 

Allowed). 

Date: November 22, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E72A, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Frank S. De Silva, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3E72A, Rockville, MD 

20892, (240) 669–5023, fdesilva@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 18, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24543 Filed 10–22–24; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES